Business Context and Reporting Period
This Form 8-K is filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on May 10, 2022. The filing serves to announce the Company's financial results for the first quarter ended March 31, 2022, along with other recent corporate updates. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Irvine, California.
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific numerical values within this document.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The filing text does not provide a clear value regarding specific material changes versus the prior comparable period. It only indicates that such results were reported in the accompanying press release.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (Ticker: RPHM), as the input metadata incorrectly listed "Onkure Therapeutics, Inc."
- Review Exhibit 99.1 (Press Release dated May 10, 2022) to obtain actual Q1 2022 financial figures, as they are not present in the 8-K cover text.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.
- Note that the financial information in this specific 8-K item is furnished, not filed, limiting its legal liability under Section 18 of the Exchange Act.